You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Synthetic Universal Flu Vaccine
SBC: TRIA BIOSCIENCE CORP. Topic: NCIRDAbstract Type A and B Influenza viruses cause severe seasonal epidemics and less frequent but more deadly pandemic infectionsVaccination provides the best protectionalthough serious problems are confronting the global Influenza marketVirus diversity and mutation rates necessitate the annual production of hundreds of millions of vaccines using antiquated egg based technologiesCompounding this is th ...
SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Engineering Nanoparticle Alum Adjuvants for Pandemic Influenza Vaccines
SBC: HDT BIO CORP Topic: NCIRDProject Summary SignificanceSinceavian influenza AH Nhas sickened overpeople with amortality rateHalf of all cases occurred inwhich also saw the emergence of a highly pathogenic strainThusH Navian influenza is poised to emerge as a devastating pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccineswhether attenuatedinactivatedsplit or recombinantare insufficiently imm ...
SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention -
A therapeutic approach for potential prevention of aromatase inhibitor-induced bone loss
SBC: NANOMEDIC INC Topic: NIAAbstractIn this SBIR Phase I applicationour goal is to demonstrate proof of concept of our lead chelating agent as a potential therapeutic for the prevention of osteoporosis induced by aromatase inhibitorAItherapy in postmenopausal women with hormone receptor positive breast cancerAlthough AI therapy shows great improvements in cancer free and overall survivalits treated patients face a risk of os ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Exercise Evaluation and Recovery Therapy(EXERT)
SBC: Korosensor.Com, Inc. Topic: NIAAbstract Eden MedicalIncis pleased to submit this PhaseSBIR proposal to develop the Exercise Evaluation and Recovery TherapyEXERTsystema mobile healthmHealthsolution for assessing exercise impairment of adult peripheral vascular diseasePVDpatients and increasing their exercise capacityOvertaxing during exercise could be highly dependent on muscle oxidative capacity and muscle deoxygenationWhile th ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Enhanced Treatment Management of Opioid-Dependence in an Office-Based Setting
SBC: MedicaSafe Inc Topic: NIDAPROJECT SUMMARY ABSTRACT Opioid use disorder is the leading cause of accidental death in the USwith overlethal drug overdoses inSAMHSA estimates thatmillion Americans misuse prescription opioids for non medical purposes annuallyPublic health officials and policymakers have acknowledged the urgent need for innovative approaches to the treatment of those with opioid use disorderin spite of thisthe a ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
OnTRACK: Mobile Application for Pediatric Post-TBI Patient Management
SBC: CREARE LLC Topic: NCIPCPROJECT SUMMARYCreare and its clinical and research partners propose to develop a software platformOnTRACKOnline Treatment Recovery Assistance for Concussion in Kidsfor children and adolescents recovering from concussion or mild traumatic brain injurymTBIThe platform includes a mobile applicationappfor the patients and their care teamparentsteacherscoachesetca database serverand a decision support ...
SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Tau oligomer platform validation using lead series candidate in htau mice
SBC: OLIGOMERIX INC Topic: NIATITLETau oligomer platform validation using lead series candidate in htau mice PROJECT SUMMARYSBIR Funding OpportunityAdvancing Research on Alzheimerandapos s DiseaseADand Alzheimerandapos s Disease Related DementiasADRDRRPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand related tauopathiesThere is a critical unmet need for a di ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Gene and Stem Cell-Based Treatment for Tendinopathy
SBC: NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC Topic: RProject SummaryTendinopathy is a common chronic tendon disorder that affectsof individuals overyears oldIt is characterized by painswellingloss of functionand impaired performanceThere is currently no cure for tendinopathySpontaneous repair or treatment typically leads to scar formationresulting in a weakened tissue with reduced function and mechanical properties that may ultimately rupture with f ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD
SBC: OLIGOMERIX INC Topic: NIAPROJECT SUMMARYSBIR RRFast Track ApplicationFOA NumberPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand AD related dementiasADRDwith tau pathologyThere is a critical unmet need for a disease modifying drugDMDfor ADChronic treatment strategies require safeeffectiveand economically feasible approaches such as small molecule drugsT ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development and validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 103Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health